Pharmacologic class (EPC) · 10 drug pages

Anti-coagulant: adverse event reports filed with FDA

28,971 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

28,971
reports across the class: 0.1% of all reports; 1,464
reports, 12 months to June 2026: 1,609 in the 12 months before; 55.7%
marked serious by the reporter: 57.4% across all reports; 10
drugs with a page: brand and generic names counted separately

Anti-coagulant is a pharmacologic class (an FDA Established Pharmacologic Class) with 10 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 28,971 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026.

1,464 reports arrived in the 12 months to June 2026, close to the 1,609 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 55.7% of the class's reports are marked serious, 17.2% record death among the outcomes and 23.8% record hospitalisation, as reported.

Across the class the reactions recorded most often are paraesthesia (20.2%), nausea (16.9%) and dizziness (11.9%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Heparin sodium	generic	13,350	845	68%	Heparin-induced thrombocytopenia
Anticoagulant Sodium CitrateTrisodium citrate dihydrate	brand	6,781	80	2.4%	Paraesthesia
FragminDalteparin sodium	brand	3,327	220	79.1%	Pulmonary embolism
Dalteparin sodium	generic	1,298	63	95.5%	Nausea
Argatroban	generic	1,062	52	85.1%	Drug ineffective
Bivalirudin	generic	706	41	90.7%	Drug ineffective
Sodium citrate	generic	624	44	95.2%	Abdominal distension
Potassium citrate	generic	616	64	41.4%	Drug ineffective
ClenpiqSodium picosulfate, magnesium oxide, and anhydrous citric acid	brand	616	31	17.4%	Drug ineffective
Heparin Sodium in DextroseHeparin sodium and dextrose	brand	591	24	88.7%	Drug ineffective

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Paraesthesiatingling or pins and needles20.2%5,844
Nauseafeeling sick16.9%4,894
Dizzinesslight-headedness or unsteadiness11.9%3,440
Feeling hotfeeling hot10.2%2,967
Pallor9.4%2,715
Hyperhidrosisexcessive sweating9%2,606
Drug ineffectivethe medicine did not work as expected8.1%2,352
Astheniaweakness or lack of energy6.6%1,919
Heparin-induced thrombocytopenia6.6%1,910
Abdominal painstomach or belly pain6.2%1,796
Vomitingbeing sick6%1,733
Adverse eventan unwanted medical event, type not specified5%1,461
Thirst4.8%1,405
Dyspnoeashortness of breath4.6%1,329
Off label useused for a purpose or in a way not on the label4.6%1,328
Vision blurredblurred vision4.4%1,280
Sepsisa severe body-wide response to infection4.3%1,252
Hypotensionlow blood pressure4.3%1,237
Pulmonary embolisma blood clot in the lung4.1%1,200
Dysgeusiaaltered taste4%1,172
Drug hypersensitivityan allergic-type reaction to a medicine3.8%1,094
Thrombosis3.7%1,078
General physical health deteriorationgeneral decline in health3.6%1,034
Multiple organ dysfunction syndromeseveral organs failing3.6%1,033
Cardiogenic shockshock from the heart failing to pump3.5%1,018

Solid bar: share of all class reports. Hollow bar: the median share across the 10 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death17.2%4,988

Life-threatening10.1%2,927

Hospitalisation (initial or prolonged)23.8%6,909

Disability4.2%1,218

Congenital anomaly1.4%409

Other serious37.8%10,951

Not serious44.3%12,830

Patient age

Under 20.7%215

2 to 110.6%186

12 to 170.5%144

18 to 4427.1%7,846

45 to 6419.7%5,714

65 to 7411.6%3,360

75 and over13.4%3,877

Age not given26.3%7,629

Who reported

Physician17.4%5,055

Pharmacist11.6%3,348

Other health professional49.5%14,351

Lawyer7.5%2,160

Consumer or non-health professional10.2%2,949

Not given3.8%1,108

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Anti-coagulant reports

Which drugs are in the Anti-coagulant class on this site?

Heparin sodium, Anticoagulant Sodium Citrate, Fragmin, Dalteparin sodium, Argatroban and Bivalirudin and 4 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

28,971 reports through June 2026, 1,464 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

paraesthesia (20.2%), nausea (16.9%), dizziness (11.9%), feeling hot (10.2%) and pallor (9.4%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.